Background: The novel direct oral anticoagulants (NOA), dabigatran (a thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors) have shown at least noninferiority compared to
Additional file 3: 3.0 CRF Screening. PDF file. Study recruitment – prescreening / screening. Clinical record form for prescreening / screening data. 3.1 CRF Adherence Checklist. PDF file. Baseline vi